Pionyr Immunotherapeutics


Pionyr is exploiting novel target discovery and antibody generation platform technologies to create novel immuno-oncology therapeutics targeting the tumor microenvironment. The company’s initial approach, termed “Myeloid Tuning,” is designed to enhance the immune system’s antitumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity. Pionyr has several Myeloid Tuning programs in late preclinical development for solid tumors.